287 related articles for article (PubMed ID: 24824295)
1. Platelet-related fibrinolysis resistance in patients suffering from PV. Impact of clot retraction and isovolemic erythrocytapheresis.
Rusak T; Piszcz J; Misztal T; Brańska-Januszewska J; Tomasiak M
Thromb Res; 2014 Jul; 134(1):192-8. PubMed ID: 24824295
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: the effect of isovolemic erythrocytapheresis.
Rusak T; Ciborowski M; Uchimiak-Owieczko A; Piszcz J; Radziwon P; Tomasiak M
Platelets; 2012; 23(6):455-62. PubMed ID: 22098131
[TBL] [Abstract][Full Text] [Related]
3. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
Misztal T; Rusak T; Brańska-Januszewska J; Ostrowska H; Tomasiak M
Free Radic Biol Med; 2015 Dec; 89():533-47. PubMed ID: 26454084
[TBL] [Abstract][Full Text] [Related]
4. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.
Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
Thromb Res; 1998 Apr; 90(2):51-6. PubMed ID: 9684757
[TBL] [Abstract][Full Text] [Related]
5. [Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera].
Pósán E; Ujj G; Kiss A; Telek B; Rák K; Udvardy M
Orv Hetil; 1996 Jan; 137(2):71-4. PubMed ID: 8721871
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients.
Rusak T; Misztal T; Piszcz J; Tomasiak M
Free Radic Res; 2014 Feb; 48(2):230-8. PubMed ID: 24180690
[TBL] [Abstract][Full Text] [Related]
7. Reduced clot retraction rate and altered platelet energy production in patients with asthma.
Tomasiak-Lozowska MM; Rusak T; Misztal T; Bodzenta-Lukaszyk A; Tomasiak M
J Asthma; 2016 Aug; 53(6):589-98. PubMed ID: 27145190
[TBL] [Abstract][Full Text] [Related]
8. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D
Platelets; 2012; 23(1):36-44. PubMed ID: 21787173
[TBL] [Abstract][Full Text] [Related]
9. Peroxynitrite may affect clot retraction in human blood through the inhibition of platelet mitochondrial energy production.
Misztal T; Rusak T; Tomasiak M
Thromb Res; 2014 Mar; 133(3):402-11. PubMed ID: 24388569
[TBL] [Abstract][Full Text] [Related]
10. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
11. Clinically relevant HOCl concentrations reduce clot retraction rate via the inhibition of energy production in platelet mitochondria.
Misztal T; Rusak T; Tomasiak M
Free Radic Res; 2014 Dec; 48(12):1443-53. PubMed ID: 25236568
[TBL] [Abstract][Full Text] [Related]
12. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
13. [Micromethod for simultaneous determination of retraction, spontaneous fibrinolysis, and hemostatic properties of blood clots].
Bandarin VA; Ivanov EP; Siatkovskiĭ VA; Trusov LN
Lab Delo; 1971; 12():716-20. PubMed ID: 4111441
[No Abstract] [Full Text] [Related]
14. PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN).
Giaccherini C; Verzeroli C; Marchetti M; Gamba S; Piras F; Russo L; Tessarolo S; Vignoli A; Finazzi G; Rambaldi A; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S185-6. PubMed ID: 27161713
[TBL] [Abstract][Full Text] [Related]
15. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
16. High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry.
Westbury SK; Lee K; Reilly-Stitt C; Tulloh R; Mumford AD
Thromb Res; 2013 Aug; 132(2):e145-51. PubMed ID: 23906940
[TBL] [Abstract][Full Text] [Related]
17. Global coagulation in myeloproliferative neoplasms.
Tripodi A; Chantarangkul V; Gianniello F; Clerici M; Lemma L; Padovan L; Gatti L; Mannucci PM; Peyvandi F
Ann Hematol; 2013 Dec; 92(12):1633-9. PubMed ID: 23820940
[TBL] [Abstract][Full Text] [Related]
18. Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation.
Gajos G; Siniarski A; Natorska J; Ząbczyk M; Siudut J; Malinowski KP; Gołębiowska-Wiatrak R; Rostoff P; Undas A
Cardiovasc Diabetol; 2018 Nov; 17(1):146. PubMed ID: 30466424
[TBL] [Abstract][Full Text] [Related]
19. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
